CD8A and neoplasm: Emactuzumab, another monoclonal antibody against CSF1, enhances anti-tumor immune responses by decreasing the number of F4/80+ TAMs within tumors and increasing the CD8+/CD4+ T cell ratio through inhibition of the CSF1/CSF1R-signaling pathway (164).